MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-07-2023
Eargo Revenue 2011-2026 | EAR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.2 M | 32.1 M | 69.2 M | 32.8 M | 23.2 M | 6.62 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69.2 M | 6.62 M | 33.5 M |
Quarterly Revenue Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.27 M | 8.11 M | 11.8 M | - | 7.91 M | 7.25 M | 9.18 M | - | - | 22.9 M | 22 M | - | 18.2 M | 15.9 M | 12.7 M | - | 7.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | 7.25 M | 12.7 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
3.37 B | $ 39.27 | -1.36 % | $ 5.85 K | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
443 M | $ 7.82 | - | $ 561 M |  Israel |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.99 | - | $ 149 M |  France |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 9.4 | - | $ 1.27 B | USA |
 |
FONAR Corporation
FONR
|
97.6 M | $ 18.5 | -0.32 % | $ 121 M | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 43.41 | - | $ 1.35 B | USA |
 |
Electromed
ELMD
|
64 M | $ 23.98 | - | $ 203 M | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
225 M | $ 29.83 | - | $ 1.37 B | USA |
 |
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.17 | -3.35 % | $ 110 M | USA |
 |
InMode Ltd.
INMD
|
358 M | $ 13.6 | - | $ 879 M | Israel |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.43 | 1.42 % | $ 23.1 M | USA |
 |
IRadimed Corporation
IRMD
|
73.2 M | $ 104.29 | - | $ 1.32 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Accuray Incorporated
ARAY
|
459 M | $ 0.53 | - | $ 54.5 M | USA |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M | Israel |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 68.43 | -2.62 % | $ 3.73 B |  Britain |
 |
Pulmonx Corporation
LUNG
|
83.8 M | $ 1.53 | - | $ 59.8 M | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.8 | 6.81 % | $ 43.5 M | USA |
 |
Align Technology
ALGN
|
4 B | $ 182.64 | - | $ 13.7 B | USA |
 |
Medtronic PLC
MDT
|
33.5 B | $ 96.71 | - | $ 124 B | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Inari Medical
NARI
|
383 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
82.1 M | $ 3.68 | - | $ 779 M | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
44.3 B | $ 113.61 | - | $ 198 B | USA |
 |
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 73.85 | - | $ 109 B | USA |